MedPath

Ayurveda management of Bronchial Asthma.

Phase 2
Conditions
Health Condition 1: J459- Other and unspecified asthma
Registration Number
CTRI/2019/04/018376
Lead Sponsor
Government Ayurved CollegeNagpur
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1) Patients having sign and symptoms of tamak shvasa according to classics.

2) Patient showing symptoms, sign and medical history of bronchial asthma will be included.

3) Patients having respiratory rate in between 22 to 42 per minute will be included.

4) Patients suffering from this disease since 1 to 4 years will be included in study.

5) Patient with mild to moderate exacerbation of Bronchial asthma

6)patient willing and able to participate for 2 months.

7) Positive test of reversibility:

a] symptomatic patients - An improvement of 60 L/min or >20% in PEFR 10 min after inhalation of bronchodilator.

b] Asymptomatic patient 60 L/min or >20% fall in PEFR by provocation with 5-10 min of physical exercise followed by reversal upon inhalation of bronchodilator when assessed after 10 min.

Exclusion Criteria

1) Patients having major diseases like AIDS, renal and cardio vascular diseases will be rejected.

2) If any patient discontinues the treatment will be excluded from this study.

3) Patients with severe asthma exacerbation.

4) Patient who is pregnant or lactating will be excluded.

5) Patients with poorly controlled Hypertension [ >160/100mmhg]

6) Patients with uncontrolled Diabetes Mellitus [ Blood sugar fasting > 130 mg / dl and post meal 250 mg / dl]

7) Patients with active lung disease other than Bronchial asthma.

8) Patients who had major surgery within 2 weeks prior to screening visited.

9) Patients with a known diagnosis of human immunodeficiency virus.

10) Patients with evidence of malignancy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1)To evaluate the efficacy of Kiratadi Kwath in the management of Tamak Shvasa <br/ ><br>specifically on PEFR, SMI. <br/ ><br>2) To compare the effect of Kiratadi Kwath in trial group with Tablet Deriphylline 150 mg <br/ ><br>in control group. <br/ ><br>Timepoint: 1)On zero day assessments i.e B.T value. <br/ ><br>2)For trial group Kiratadi Kwath and for control group tablet Deriphylline will be given for 45 days. <br/ ><br>3)followed up and assessments will be done every 15 days. <br/ ><br>4)Final assessment will be done on 45th day. <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
1)To study Tamak Shvasa in detail from Ayurvedic perspective. <br/ ><br>2)To study Tamak Shvasa which is correlated with Bronchial asthma with modern point of view.Timepoint: one and half year.
© Copyright 2025. All Rights Reserved by MedPath